What Can We Expect From Bluebirdbio (NASDAQ:BLUE) After ROTH Capital’s Latest Coverage?


Why Has ROTH Capital Given Bluebirdbio (NASDAQ:BLUE) a $121.0 Price Target

ROTH Capital has just issued a Buy rating for Bluebirdbio (NASDAQ:BLUE) shares. The firm have commenced coverage coverage on shares of BLUE in a comprehensive report issued to investors and clients on 3 December. This target may suggest upside of 49.36% from the previous close of Bluebirdbio (NASDAQ:BLUE).

From a total of 10 analysts covering bluebird bio (NASDAQ:BLUE) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $204 while the lowest target price is $108. The mean of all analyst targets is $160.4 with a 101.21% above today’s ($83.99) stock price. bluebird bio was the topic of 11 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs initiated shares on November 18 with “Buy” rating. JP Morgan maintained shares with “Overweight” rating and $244 target share price in a report from an August 24. Jefferies initiated BLUE stock in a recent report from October 23 with “Buy” rating. Roth Capital maintained the rating on August 15. Roth Capital has a “Buy” rating and a $192 price target on shares. Finally, Morgan Stanley upgraded the stock to “Overweight” rating in a report issued on an October 5.

Approximately shares of stock traded hands. bluebird bio Inc (NASDAQ:BLUE) has declined 39.18% since April 30, 2015 and is downtrending. It has underperformed by 38.89% the S&P500.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has a market cap of $2.95 billion. The Firm is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. It currently has negative earnings. The Company’s products include Lenti-D, LentiGlobin and CAR T Cells.

According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.” Get a free copy of the Zacks research report on bluebird bio Inc (BLUE).